Profluent, Lilly Partner to Advance AI Gene Editing Tech
EMERYVILLE, CALIFORNIA, April 29, 2026 Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
EMERYVILLE, CALIFORNIA, April 29, 2026 Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to...
